In Vivo Impact of CpG1826 Oligodeoxynucleotide on CD8 T Cell Primary Responses and Survival

Laurent Beloeil, Martine Tomkowiak, Georgi Angelov, Thierry Walzer, Patrice Dubois and Jacqueline Marvel

*J Immunol* 2003; 171:6297; doi: 10.4049/jimmunol.171.11.6297
http://www.jimmunol.org/content/171/11/6297.1

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
CORRECTIONS


In *Materials and Methods*, in the first sentence under the heading *Vaccination protocol*, an extra T was added to the 5′ end of the CpG1826 sequence. The correct sequence is 5′-TCC ATG ACG TTC CTG ACG TT-3′. The authors wish to underline that CpG1826 has a phosphorothioate backbone.

Also in this section, in the second sentence under the heading *CFSE labeling of F5 TCR transgenic cells and adoptive transfers*, there is a mistake in the CFSE concentration. For adoptive transfer, the CFSE concentration used is 7.5 μM (instead of 0.75 μM). Under the heading *In vivo cytotoxic assays*, in the fifth sentence, CFSE concentrations for target cells are 7.5 μM (pulsed B10) and 0.75 μM (non-pulsed B10), and in the seventh sentence when three targets are used: 7.5 μM (pulsed B10), 0.94 μM (pulsed B6-Lpr) and 0.14 μM (non-pulsed B10).


In *Results*, the legends for Figures 2 and 3 are inverted. The legend with Figure 2 should have been published with the image for Figure 3, and vice versa.


The second author’s first name was misspelled. The correct spelling is Hsi-Hsien.